Figure 2.
Figure 2. Specific immune responses (assessed by ELISPOT assays for granzyme B) against RHAMM/CD168 R3- and R5-pulsed T2 cells in an AML patient (patient 2 in Table 1) with a long-term complete remission over 8 years. No T-cell reaction was found for the negative control (T2 cells without peptide) and for the RHAMM/CD168-derived peptides R1 and R9. Cross-reactivity against an irrelevant peptide was excluded. All assays were performed in triplicate. The figure shows the results of a representative experiment. Error bars indicate standard deviation.

Specific immune responses (assessed by ELISPOT assays for granzyme B) against RHAMM/CD168 R3- and R5-pulsed T2 cells in an AML patient (patient 2 inTable 1 ) with a long-term complete remission over 8 years. No T-cell reaction was found for the negative control (T2 cells without peptide) and for the RHAMM/CD168-derived peptides R1 and R9. Cross-reactivity against an irrelevant peptide was excluded. All assays were performed in triplicate. The figure shows the results of a representative experiment. Error bars indicate standard deviation.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal